10/550039

PETITION FOR REVIVAL OF AN INTERNATIONAL APPLICATION FOR PATENT DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)	Docket Number (Optional) 100870-1P-US

First Named Inventor: Michael Barry Gravestock

International (PCT) Application No.: PCT/GB2004/001119

U.S. Application No.:
(if known)

Filed: March 20, 2003

Title: Antibacterial 1,3-Oxazolidin-2-one Derivatives

Attention: PCT Legal Staff
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The above-identified application became abandoned as to the United States because the fees and documents required by 35 U.S.C. 371(c) were not filed prior to the expiration of the time set in 37 CFR 1.495(b) or (c) as applicable. The date of abandonment is the day after the date on which the 35 U.S.C. 371(c) requirements were due. See 37 CFR 1.495(h).

APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION

NOTE: A grantable petition requires the following items:
- (1) Petition fee
- (2) Proper reply
- (3) Terminal disclaimer with disclaimer fee which is required for all international applications having an international filing date before June 8, 1995; and
- (4) Statement that the entire delay was unintentional.

1. Petition fee
   - ☐ Small entity - fee $_____(37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27.

   - ☒ Other than small entity - fee $ See 1 _____(37 CFR 1.17(m))

 Proper reply

A. The proper reply (the missing 35 U.S.C. 371(c) requirement(s)) in the form of Form PTO-1390 _____ (identify type of reply):

   - ☒ has been filed previously on _____ See 2 in Addendum _____.

   - ☒ is enclosed herewith.

10/25/2005 LLANDGRA 00000002 10550039

01 FC:1453   1500.00 DA

PTO/SB/64/PCT (12-04)
Approved for use through 03/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

3. Terminal disclaimer with disclaimer fee

[X] Since this international application has an international filing date on or after June 8, 1995, no terminal disclaimer is required.

[ ] A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of $ _____ for a small entity or $_____ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).

4. Statement. The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

_____
Signature

Sept. 23
Date

Heidi M. Berven
_____
Typed or Printed Name

48,951
_____
Registration Number, if applicable

AstraZeneca R&D Boston
_____
Address

781-839-4336
_____
Telephone Number

35 Gatehouse Drive Waltham MA 02451
_____
Address

Enclosures: [X] Response

[X] Fee Payment

[ ] Terminal Disclaimer

[X] Other (please identify): *Copies of Form 1390 and associated information*